Surface Localization of Glucosylceramide during Cryptococcus neoformans Infection Allows Targeting as a Potential Antifungal Cerezyme as an Antifungal
2011

Targeting Glucosylceramide in Cryptococcus neoformans Infection

Sample size: 10 publication 10 minutes Evidence: high

Author Information

Author(s): Rhome Ryan, Singh Arpita, Kechichian Talar, Drago Monica, Morace Giulia, Luberto Chiara, Poeta Maurizio Del

Primary Institution: Medical University of South Carolina

Hypothesis

Can targeting glucosylceramide in Cryptococcus neoformans improve treatment outcomes?

Conclusion

Cerezyme treatment significantly reduces glucosylceramide levels and prolongs survival in mice infected with Cryptococcus neoformans.

Supporting Evidence

  • Cerezyme treatment reduced glucosylceramide levels in vitro and in vivo.
  • Mice treated with Cerezyme showed increased survival compared to untreated controls.
  • Glucosylceramide localization increased during infection conditions.
  • Δgcs1 mutant strain was avirulent in mouse models.

Takeaway

Researchers found that a drug called Cerezyme can help fight a fungus that makes people sick by breaking down a specific fat it uses to survive.

Methodology

The study used immunofluorescence, mass spectrometry, and mouse models to assess glucosylceramide localization and the effects of Cerezyme treatment.

Potential Biases

Potential bias in the interpretation of results due to the use of a single treatment method.

Limitations

The study did not fully explore the effects of Cerezyme in all possible conditions of infection.

Participant Demographics

Mice used in the study were female CBA/J, aged 4-6 weeks.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1371/journal.pone.0015572

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication